Återgå till huvudnavigering Återgå till sök Gå direkt till huvudinnehållet

Polymeric antigen BLSOmp31 formulated with class B CpG-ODN in a nanostructure (BLSOmp31/CpG-ODN/Coa-ASC16) administered by parenteral or mucosal routes confers protection against Brucella ovis in Balb/c mice

  • Maria Celeste Moran
  • , Angel Ricardo Bence
  • , Maria Fernanda Sanchez Vallecillo
  • , Claudia Maria Lutzelschwab
  • , Marcelo Gaston Rodriguez
  • , Romina Pardo
  • , Fernando Alberto Goldbaum
  • , Vanesa Zylberman
  • , Santiago Daniel Palma
  • , Belkys Angelica Maletto
  • , Silvia Marcela Estein
  • , et al.

    Publikation: Bidrag till tidskrift › Artikel i vetenskaplig tidskrift › Peer review

    Sammanfattning

    Previously, we demonstrated that the chimera BLSOmp31 formulated in chitosan microspheres or Poloxamer407-Chitosan administered via the nasal and the ocular mucosa conferred partial protection in sheep against B. ovis. In this work, we tested a new delivery system for mucosal immunization with BLSOmp31 in the murine model to improve the efficacy of previously used formulations. First, we evaluated the protective efficacy against B. ovis induced by BLSOmp31 administered by the subcutaneous route using either BLSOmp31 alone, coadministered with immunostimulatory synthetic oligodeoxynucleotides containing unmethylated cytosineguanine motifs (CpG-ODN) or with CpG-ODN in a nanostructure called Coa-ASC16 compared with BLSOmp31 emulsified in Incomplete Freund Adjuvant. Then, we evaluated the protection conferred by the best performing formulation (BLSOmp31/CpG-ODN/Coa-ASC16) administered by both subcutaneous and ocular routes. BLSOmp31/CpG-ODN/Coa-ASC16 injected subcutaneously did not induce higher IgG antibody levels compared to BLSOmp31 alone or BLSOmp31/CpG-ODN but it did stimulate a mixed immune Th1-Th2 response with the highest levels of IFN-? and conferred significant protection against the B. ovis challenge. Although ocular instillation of BLSOmp31/CpG-ODN/Coa-ASC16 showed a similar degree of protection compared to the parenteral route (3.66 and 3.60 logs of protection, respectively), it induced lower levels in serum of specific IgG (with mixed IgG1/IgG2a) and IgA antibodies and, less IFN-? and IL-4 than the subcutaneous route. No antibodies were detected in vaginal lavages or saliva. Fecal antigen-specific IgA was slightly higher in mice immunized with BLSOmp31/CpG-ODN/Coa-ASC16 subcutaneously compared with the ocular route. These results indicate that BLSOmp31/CpG-ODN/Coa-ASC16 was a safe and effective vaccine against B. ovis in mice.
    OriginalspråkEngelska
    Sidor (från-till)217-227
    Antal sidor11
    TidskriftResearch in Veterinary Science
    Volym135
    DOI
    StatusPublicerad - 2021

    FN:s SDG:er

    Detta resultat bidrar till följande hållbara utvecklingsmål:

    1. SDG 3 – God hälsa och välbefinnande
      SDG 3 – God hälsa och välbefinnande

    Nyckelord

    • BLSOmp31
    • CpG-ODN
    • Coa-ASC16
    • Experimental vaccine
    • Immune response
    • Brucella ovis
    • Protection
    • Murine model

    Citera det här